Catalyst Pharmaceuticals Announces Positive Phase 3 Clinical Trial Results

On November 27, Catalyst Pharmaceutical, Inc. (CPRX) announced positive phase 3 clinical trial results from its drug Firdapse. This was the second phase 3 trial of Firdapse, which shows statistically significant improvement for symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). LEMS is a rare autoimmune disorder in which nerves have trouble sending to muscle cells, which results in muscle weakness of the limbs.

 

Sonal detected the event at 6:30 am and issued an alert to its subscribers. The next trade occurred during pre-market trading at 6:52 am for $3.92. The stock opened for regular market trading at $3.18.

The stock price continued to climb higher throughout the day before closing at $3.61. That made a gain of 13.5% on the day of the event. The trend continued over the next few trading sessions. On December 4, the stock closed at $4.34 making a gain of 36% in the week following the event.

 

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!